Breast Cancer
Advertisement
The HER2DX ERBB2 mRNA score was significantly associated with improved survival in patients with metastatic HER2+ BC.
Breast cancer survivors with metabolic syndrome have shorter disease-free survival than those without metabolic syndrome.
Breast cancer survivors have a modestly increased risk of type 2 diabetes, largely driven by breast cancer treatment.
Using the HER2DX genomic tool is feasible in a real-world setting of patients with early-stage HER2-positive breast cancer.
Patients with breast cancer who have high levels of glycosylated hemoglobin have an increased risk of recurrence and death.
Breast cancer patients have an increased risk of cardiovascular disease compared with the general female population.
Women with more metabolic syndrome components face a higher risk of dying from breast cancer.
Dr. Timothy Yap discusses the PETRA trial, which showed the efficacy of saruparib in treating HER2-negative breast cancer.
Soft tumor environments can cause triple-negative breast cancer to spread more aggressively.
Patients ≥70 years of age were more likely to have a reduction in their palbociclib dosage.
Decreasing the at-home dose of dexamethasone before paclitaxel treatment may help reduce the incidence of infusion reactions.
Dr. Samilia Obeng-Gyasi discusses how social factors can impact outcomes in breast cancer patients.
For women with BRCA1 sequence variations, MRI surveillance is linked to lower breast cancer mortality.
A study found a "substantial deficit" of undiagnosed cancer cases during the COVID-19 pandemic.
Completing HBOT appears effective at reducing pain and fibrosis in patients with irradiated breast cancer.
A researcher is looking to prove that nebivolol, an FDA-approved drug for high blood pressure, is effective at treating TNBC.
Screening and new treatments have led to a US breast cancer mortality rate that is 58% lower than in it was in the mid-1970s.
The FDA recently approved a new combination therapy for the treatment of HR-positive, HER2-negative breast cancer.
CNS radiotherapy with pyrotinib and capecitabine improves CNS progression in breast cancer patients with brain metastases.
The Oncology Brothers talk with Paolo Tarantino, MD, about the TROPiCS-02 study presented at SABCS.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.